Clinical Trial Update: Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating prevention of cardiac allograft vasculopathy in heart transplant recipients using everolimus in combination with anti-CMV ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Allograft Vasculopathy
• Cytomegalovirus Infection

Drugs mentioned

• Everolimus (everolimus)
• GANCICLOVIR (GANCICLOVIR SODIUM)

Snippet

Sponsor: University of Bologna | Conditions: Heart Transplantation, Cardiac Allograft Vasculopathy | Phase 3 | Status: UNKNOWN